ConductScience.org, home

Paper34831014

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma.

Patel H and 5 others. Cancers (Basel), 2021. Cited by 27 papers, by iCite.

Cite this record

ConductScience Library. IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma. Papers, record 34831014. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34831014

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2021
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
27
iCite
Relative citation ratio, by iCite
1.34
iCite
Revised in PubMed
2021-11-30
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Patel HHima
2Mishra RRosalinhttps://orcid.org/0000-0002-9808-8797
3Yacoub NNour
4Alanazi SSamarhttps://orcid.org/0000-0002-2415-7227
5Kilroy MKMary Kate
6Garrett JTJoan T

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
W81XWH1910441United States Department of DefensePubMed

Source PubMed

Download CSV of grants

References63

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131936151Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.Cells2020https://conductscience.org/library/papers/31936151PubMed
223166326Biochemical characterization of individual human glycosylated pro-insulin-like growth factor (IGF)-II and big-IGF-II isoforms associated with cancer.J Biol Chem2013https://conductscience.org/library/papers/23166326PubMed
332150843A Possible Link of Genetic Variations in ER/IGF1R Pathway and Risk of Melanoma.Int J Mol Sci2020https://conductscience.org/library/papers/32150843PubMed
419996272BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.Mol Cancer Ther2009https://conductscience.org/library/papers/19996272PubMed
530770389Targeting Alterations in the RAF-MEK Pathway.Cancer Discov2019https://conductscience.org/library/papers/30770389PubMed
630404005BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association.Cell Rep2018https://conductscience.org/library/papers/30404005PubMed
710229198Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism.Oncogene1999https://conductscience.org/library/papers/10229198PubMed
832843616IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas.Signal Transduct Target Ther2020https://conductscience.org/library/papers/32843616PubMed
931166680Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.N Engl J Med2019https://conductscience.org/library/papers/31166680PubMed
1018300768The MAPK pathway in melanoma.Curr Opin Oncol2008https://conductscience.org/library/papers/18300768PubMed
1121521745Phosphoproteomic screen identifies potential therapeutic targets in melanoma.Mol Cancer Res2011https://conductscience.org/library/papers/21521745PubMed
1219029956Insulin and insulin-like growth factor signalling in neoplasia.Nat Rev Cancer2008https://conductscience.org/library/papers/19029956PubMed
1317473213Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.Clin Cancer Res2007https://conductscience.org/library/papers/17473213PubMed
1430833419Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway.Cancer Res2019https://conductscience.org/library/papers/30833419PubMed
1521217522Insulin-like growth factor receptor-1 (IGF-1R) expression in normal breast, proliferative breast lesions, and breast carcinoma.Appl Immunohistochem Mol Morphol2011https://conductscience.org/library/papers/21217522PubMed
1630841853iGEAK: an interactive gene expression analysis kit for seamless workflow using the R/shiny platform.BMC Genomics2019https://conductscience.org/library/papers/30841853PubMed
1729019177Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.Ann Surg Oncol2017https://conductscience.org/library/papers/29019177PubMed
1828923912Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.Cancer Discov2018https://conductscience.org/library/papers/28923912PubMed
1925452114Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma.Nat Commun2014https://conductscience.org/library/papers/25452114PubMed
2021654344Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R.Melanoma Res2011https://conductscience.org/library/papers/21654344PubMed

See all 63 referencesDownload CSV of references

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.

PMIDTitleJournalYearIn PapersSource
42196460Dynamic Time-Resolved Remodeling of the Immune Microenvironment After Resistance to BRAF/MEK Inhibitors in Melanoma: Mechanisms, Biomarkers, and Emerging Therapeutic Strategies.Int J Mol Sci2026https://conductscience.org/library/papers/42196460PubMed
42182948Association of serum vitamin D and serum vitamin C with the risk of melanoma among adults in the United States: a cross-sectional analysis of 2003-2006 and 2017-2018 NHANES data.J Clin Biochem Nutr2026https://conductscience.org/library/papers/42182948PubMed
41807883BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations.Mol Biomed2026https://conductscience.org/library/papers/41807883PubMed
40527402IGF-1R inhibitors in cancer: A review of available evidence and future outlook.Crit Rev Oncol Hematol2025https://conductscience.org/library/papers/40527402PubMed
40515636Anoikis classification of lung squamous cell carcinoma reveals correlation with clinical prognosis and immune characteristics.Ann Med2025https://conductscience.org/library/papers/40515636PubMed
40092985Inhibiting melanoma tumor growth: the role of oxidative stress-associated LINC02132 and COPDA1 long non-coding RNAs.Front Immunol2025https://conductscience.org/library/papers/40092985PubMed
40071065Targeting Surface Markers in Anaplastic Thyroid Cancer: Future Directions in Ligand-bound Therapy.J Endocr Soc2025https://conductscience.org/library/papers/40071065PubMed
38691253Pan-cancer analysis of prognostic and immunological role of IL4I1 in human tumors: a bulk omics research and single cell sequencing validation.Discov Oncol2024https://conductscience.org/library/papers/38691253PubMed
38278874BRAF - a tumour-agnostic drug target with lineage-specific dependencies.Nat Rev Clin Oncol2024https://conductscience.org/library/papers/38278874PubMed
37834284Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2.Int J Mol Sci2023https://conductscience.org/library/papers/37834284PubMed
37465678Comprehensive bioinformatics analysis reveals the crosstalk genes and immune relationship between the systemic lupus erythematosus and venous thromboembolism.Front Immunol2023https://conductscience.org/library/papers/37465678PubMed
37175614Trametinib-Resistant Melanoma Cells Displaying MITFhigh/NGFRlow/IL-8low Phenotype Are Highly Responsive to Alternating Periods of Drug Withdrawal and Drug Rechallenge.Int J Mol Sci2023https://conductscience.org/library/papers/37175614PubMed
36829149Efficient prioritization of CRISPR screen hits by accounting for targeting efficiency of guide RNA.BMC Biol2023https://conductscience.org/library/papers/36829149PubMed
36497341Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies.Cancers (Basel)2022https://conductscience.org/library/papers/36497341PubMed
35968344Nuclear interaction of Arp2/3 complex and BRAFV600E promotes aggressive behavior and vemurafenib resistance of thyroid cancer.Am J Cancer Res2022https://conductscience.org/library/papers/35968344PubMed
35912223The Evolution of BRAF Activation in Non-Small-Cell Lung Cancer.Front Oncol2022https://conductscience.org/library/papers/35912223PubMed
35565444Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy-Present State and Perspectives.Cancers (Basel)2022https://conductscience.org/library/papers/35565444PubMed
35513054The future of targeted kinase inhibitors in melanoma.Pharmacol Ther2022https://conductscience.org/library/papers/35513054PubMed
35410220Identification of IGF1R mutation as a novel predictor of efficacious immunotherapy in melanoma.J Transl Med2022https://conductscience.org/library/papers/35410220PubMed

Download CSV of cited by

Genes25

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
AKT1207PubTator's text mininghttps://conductscience.org/library/genes/207NCBI Gene
AXL558PubTator's text mininghttps://conductscience.org/library/genes/558NCBI Gene
BRAF673PubTator's text mininghttps://conductscience.org/library/genes/673NCBI Gene
CDKN2A1029PubTator's text mininghttps://conductscience.org/library/genes/1029NCBI Gene
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
EPHB22048PubTator's text mininghttps://conductscience.org/library/genes/2048NCBI Gene
ERBB32065PubTator's text mininghttps://conductscience.org/library/genes/2065NCBI Gene
GAS62621PubTator's text mininghttps://conductscience.org/library/genes/2621NCBI Gene
IGF13479PubTator's text mininghttps://conductscience.org/library/genes/3479NCBI Gene
IGF1R3480PubTator's text mininghttps://conductscience.org/library/genes/3480NCBI Gene
IGF23481PubTator's text mininghttps://conductscience.org/library/genes/3481NCBI Gene
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630NCBI Gene
INSR3643PubTator's text mininghttps://conductscience.org/library/genes/3643NCBI Gene
IRS13667PubTator's text mininghttps://conductscience.org/library/genes/3667NCBI Gene
IRS28660PubTator's text mininghttps://conductscience.org/library/genes/8660NCBI Gene
MAP2K55607PubTator's text mininghttps://conductscience.org/library/genes/5607NCBI Gene
MAP2K75609PubTator's text mininghttps://conductscience.org/library/genes/5609NCBI Gene
MAPK15594PubTator's text mininghttps://conductscience.org/library/genes/5594NCBI Gene
MAPK75598PubTator's text mininghttps://conductscience.org/library/genes/5598NCBI Gene
NRAS4893PubTator's text mininghttps://conductscience.org/library/genes/4893NCBI Gene

See all 25 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34831014

GET https://conductscience.org/api/papers/v1/34831014/references?page=2